New drug trial targets lung cancer in the brain
NCT ID NCT05465343
Summary
This study tested an oral drug called furmonertinib in patients with advanced non-small cell lung cancer (NSCLC) that had spread to the brain. The goal was to see how well the drug controlled the cancer in the brain and body, and how safe it was. It specifically enrolled 24 patients whose cancer had a common genetic change called an EGFR mutation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ethics Committee
Beijing, 100021, China
Conditions
Explore the condition pages connected to this study.